Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study

<p>Abstract</p> <p>Background</p> <p>This phase 1b study assessed the maximum tolerated dose (MTD), safety, and pharmacokinetics of motesanib (a small-molecule antagonist of VEGF receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit) administered once daily (QD) or twice daily (BID...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Sun Yu-Nien, McCoy Sheryl, Siu Lillian L, Welch Stephen, Desai Jayesh, Tebbutt Niall, Kotasek Dusan, Johnson Jessica, Adewoye Adeboye H, Price Timothy
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2011-07-01
coleção:	BMC Cancer
Acesso em linha:	http://www.biomedcentral.com/1471-2407/11/313
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!